Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

NKG2D controls natural reactivity of Vγ9Vδ2 T lymphocytes against mesenchymal glioblastoma cells.

Chauvin C, Joalland N, Perroteau J, Jarry U, Lafrance L, Willem C, Retière C, Oliver L, Gratas C, Gautreau-Rolland L, Saulquin X, Vallette FM, Vie H, Scotet E, Pecqueur C.

Clin Cancer Res. 2019 Sep 10. pii: clincanres.0375.2019. doi: 10.1158/1078-0432.CCR-19-0375. [Epub ahead of print]

PMID:
31506386
2.

An X-ray Vision for Phosphoantigen Recognition.

Dustin ML, Scotet E, Olive D.

Immunity. 2019 Apr 16;50(4):1026-1028. doi: 10.1016/j.immuni.2019.03.015.

PMID:
30995494
3.

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts.

Jarry U, Joalland N, Chauvin C, Clemenceau B, Pecqueur C, Scotet E.

J Vis Exp. 2018 Sep 1;(139). doi: 10.3791/57870.

PMID:
30222164
4.

Towards Deciphering the Hidden Mechanisms That Contribute to the Antigenic Activation Process of Human Vγ9Vδ2 T Cells.

Boutin L, Scotet E.

Front Immunol. 2018 Apr 20;9:828. doi: 10.3389/fimmu.2018.00828. eCollection 2018. Review.

5.

IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.

Joalland N, Chauvin C, Oliver L, Vallette FM, Pecqueur C, Jarry U, Scotet E.

J Immunother. 2018 Jun;41(5):224-231. doi: 10.1097/CJI.0000000000000225.

PMID:
29683891
6.

Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.

Retière C, Willem C, Guillaume T, Vié H, Gautreau-Rolland L, Scotet E, Saulquin X, Gagne K, Béné MC, Imbert BM, Clemenceau B, Peterlin P, Garnier A, Chevallier P.

Oncotarget. 2018 Jan 27;9(14):11451-11464. doi: 10.18632/oncotarget.24328. eCollection 2018 Feb 20.

7.

Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity.

Oizel K, Chauvin C, Oliver L, Gratas C, Geraldo F, Jarry U, Scotet E, Rabe M, Alves-Guerra MC, Teusan R, Gautier F, Loussouarn D, Compan V, Martinou JC, Vallette FM, Pecqueur C.

Clin Cancer Res. 2017 Oct 15;23(20):6292-6304. doi: 10.1158/1078-0432.CCR-16-3102. Epub 2017 Jul 18.

8.

The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human Vγ9Vδ2 T Cells.

Peigné CM, Léger A, Gesnel MC, Konczak F, Olive D, Bonneville M, Breathnach R, Scotet E.

J Immunol. 2017 Jun 1;198(11):4228-4234. doi: 10.4049/jimmunol.1601910. Epub 2017 May 1.

9.

Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation.

Starick L, Riano F, Karunakaran MM, Kunzmann V, Li J, Kreiss M, Amslinger S, Scotet E, Olive D, De Libero G, Herrmann T.

Eur J Immunol. 2017 Jun;47(6):982-992. doi: 10.1002/eji.201646818. Epub 2017 Apr 27.

10.

Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8+ T cells.

Chen HC, Joalland N, Bridgeman JS, Alchami FS, Jarry U, Khan MWA, Piggott L, Shanneik Y, Li J, Herold MJ, Herrmann T, Price DA, Gallimore AM, Clarkson RW, Scotet E, Moser B, Eberl M.

Immunol Cell Biol. 2017 Aug;95(7):620-629. doi: 10.1038/icb.2017.21. Epub 2017 Mar 30.

11.

Sensing of cell stress by human γδ TCR-dependent recognition of annexin A2.

Marlin R, Pappalardo A, Kaminski H, Willcox CR, Pitard V, Netzer S, Khairallah C, Lomenech AM, Harly C, Bonneville M, Moreau JF, Scotet E, Willcox BE, Faustin B, Déchanet-Merville J.

Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3163-3168. doi: 10.1073/pnas.1621052114. Epub 2017 Mar 7.

12.

BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia.

Benyamine A, Le Roy A, Mamessier E, Gertner-Dardenne J, Castanier C, Orlanducci F, Pouyet L, Goubard A, Collette Y, Vey N, Scotet E, Castellano R, Olive D.

Oncoimmunology. 2016 Apr 25;5(10):e1146843. eCollection 2016.

13.

Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors.

Jarry U, Chauvin C, Joalland N, Léger A, Minault S, Robard M, Bonneville M, Oliver L, Vallette FM, Vié H, Pecqueur C, Scotet E.

Oncoimmunology. 2016 Mar 30;5(6):e1168554. doi: 10.1080/2162402X.2016.1168554. eCollection 2016 Jun.

14.

RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor.

Sebestyen Z, Scheper W, Vyborova A, Gu S, Rychnavska Z, Schiffler M, Cleven A, Chéneau C, van Noorden M, Peigné CM, Olive D, Lebbink RJ, Oostvogels R, Mutis T, Schuurhuis GJ, Adams EJ, Scotet E, Kuball J.

Cell Rep. 2016 May 31;15(9):1973-85. doi: 10.1016/j.celrep.2016.04.081. Epub 2016 May 19.

15.

Vγ9Vδ2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy.

Werter IM, Schneiders FL, Scotet E, Verheul HM, de Gruijl TD, van der Vliet HJ.

Oncoimmunology. 2014 Dec 8;3(9):e955343. eCollection 2014 Oct.

16.

Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.

Schneiders FL, Huijts CM, Mantici A, Menks MA, Scotet E, Veerhuis R, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2015 May;158(1):92-9. doi: 10.1016/j.clim.2015.03.007. Epub 2015 Mar 18.

PMID:
25796193
17.

Development of Predictive Value of Urinary Cytokine Profile Induced During Intravesical Bacillus Calmette-Guérin Instillations for Bladder Cancer.

Rigaud J, Leger A, Devilder MC, Bouchot O, Bonneville M, Scotet E.

Clin Genitourin Cancer. 2015 Aug;13(4):e209-e215. doi: 10.1016/j.clgc.2015.01.005. Epub 2015 Jan 21.

PMID:
25735197
18.

Molecules and Mechanisms Implicated in the Peculiar Antigenic Activation Process of Human Vγ9Vδ2 T Cells.

Harly C, Peigné CM, Scotet E.

Front Immunol. 2015 Jan 5;5:657. doi: 10.3389/fimmu.2014.00657. eCollection 2014. Review.

19.

CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis.

Schneiders FL, Prodöhl J, Ruben JM, O'Toole T, Scheper RJ, Bonneville M, Scotet E, Verheul HM, de Gruijl TD, van der Vliet HJ.

Cancer Immunol Res. 2014 Aug;2(8):732-40. doi: 10.1158/2326-6066.CIR-13-0167. Epub 2014 Apr 21.

20.

The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells.

Sandstrom A, Peigné CM, Léger A, Crooks JE, Konczak F, Gesnel MC, Breathnach R, Bonneville M, Scotet E, Adams EJ.

Immunity. 2014 Apr 17;40(4):490-500. doi: 10.1016/j.immuni.2014.03.003. Epub 2014 Apr 3.

21.

Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.

Santolaria T, Robard M, Léger A, Catros V, Bonneville M, Scotet E.

J Immunol. 2013 Aug 15;191(4):1993-2000. doi: 10.4049/jimmunol.1300255. Epub 2013 Jul 8.

22.

Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells.

Mangan BA, Dunne MR, O'Reilly VP, Dunne PJ, Exley MA, O'Shea D, Scotet E, Hogan AE, Doherty DG.

J Immunol. 2013 Jul 1;191(1):30-4. doi: 10.4049/jimmunol.1300121. Epub 2013 Jun 5.

23.

A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.

Zhao RY, Mifsud NA, Xiao K, Chan KF, Oveissi S, Jackson HM, Dimopoulos N, Guillaume P, Knights AJ, Lowen T, Robson NC, Russell SE, Scotet E, Davis ID, Maraskovsky E, Cebon J, Luescher IF, Chen W.

PLoS One. 2012;7(9):e44707. doi: 10.1371/journal.pone.0044707. Epub 2012 Sep 6.

24.

Full restoration of Brucella-infected dendritic cell functionality through Vγ9Vδ2 T helper type 1 crosstalk.

Ni M, Martire D, Scotet E, Bonneville M, Sanchez F, Lafont V.

PLoS One. 2012;7(8):e43613. doi: 10.1371/journal.pone.0043613. Epub 2012 Aug 22.

25.

The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies.

Palakodeti A, Sandstrom A, Sundaresan L, Harly C, Nedellec S, Olive D, Scotet E, Bonneville M, Adams EJ.

J Biol Chem. 2012 Sep 21;287(39):32780-90. Epub 2012 Jul 30.

26.

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset.

Harly C, Guillaume Y, Nedellec S, Peigné CM, Mönkkönen H, Mönkkönen J, Li J, Kuball J, Adams EJ, Netzer S, Déchanet-Merville J, Léger A, Herrmann T, Breathnach R, Olive D, Bonneville M, Scotet E.

Blood. 2012 Sep 13;120(11):2269-79. doi: 10.1182/blood-2012-05-430470. Epub 2012 Jul 5.

27.

Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.

Schneiders FL, de Bruin RC, Santegoets SJ, Bonneville M, Scotet E, Scheper RJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2012 Feb;142(2):194-200. doi: 10.1016/j.clim.2011.10.006. Epub 2011 Nov 4.

PMID:
22122798
28.

Up-regulation of cytolytic functions of human Vδ2-γ T lymphocytes through engagement of ILT2 expressed by tumor target cells.

Harly C, Peyrat MA, Netzer S, Déchanet-Merville J, Bonneville M, Scotet E.

Blood. 2011 Mar 10;117(10):2864-73. doi: 10.1182/blood-2010-09-309781. Epub 2011 Jan 13.

29.

NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals.

Nedellec S, Sabourin C, Bonneville M, Scotet E.

J Immunol. 2010 Jul 1;185(1):55-63. doi: 10.4049/jimmunol.1000373. Epub 2010 May 28.

30.

Human Vgamma9Vdelta2 T cells: from signals to functions.

Nedellec S, Bonneville M, Scotet E.

Semin Immunol. 2010 Aug;22(4):199-206. doi: 10.1016/j.smim.2010.04.004. Epub 2010 May 5. Review.

PMID:
20447835
31.

Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells.

Devilder MC, Allain S, Dousset C, Bonneville M, Scotet E.

J Immunol. 2009 Sep 15;183(6):3625-33. doi: 10.4049/jimmunol.0901571. Epub 2009 Aug 26.

32.

Modulation of inflammation through IL-17 production by gammadelta T cells: mandatory in the mouse, dispensable in humans?

Deknuydt F, Scotet E, Bonneville M.

Immunol Lett. 2009 Dec 2;127(1):8-12. doi: 10.1016/j.imlet.2009.08.003. Epub 2009 Aug 12. Review.

PMID:
19682496
33.

IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.

Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E.

J Immunol. 2009 Mar 15;182(6):3423-31. doi: 10.4049/jimmunol.0803068.

34.

Bridging innate and adaptive immunity through gammadelta T-dendritic cell crosstalk.

Scotet E, Nedellec S, Devilder MC, Allain S, Bonneville M.

Front Biosci. 2008 May 1;13:6872-85. Review.

PMID:
18508701
35.

CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells.

Thedrez A, de Lalla C, Allain S, Zaccagnino L, Sidobre S, Garavaglia C, Borsellino G, Dellabona P, Bonneville M, Scotet E, Casorati G.

Blood. 2007 Jul 1;110(1):251-8. Epub 2007 Mar 15.

36.

Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?

Thedrez A, Sabourin C, Gertner J, Devilder MC, Allain-Maillet S, Fournié JJ, Scotet E, Bonneville M.

Immunol Rev. 2007 Feb;215:123-35. Review.

PMID:
17291284
37.

CXCR5 identifies a subset of Vgamma9Vdelta2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production.

Caccamo N, Battistini L, Bonneville M, Poccia F, Fournié JJ, Meraviglia S, Borsellino G, Kroczek RA, La Mendola C, Scotet E, Dieli F, Salerno A.

J Immunol. 2006 Oct 15;177(8):5290-5.

38.

Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors.

Bonneville M, Scotet E.

Curr Opin Immunol. 2006 Oct;18(5):539-46. Epub 2006 Jul 25. Review.

PMID:
16870417
39.

Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation.

Devilder MC, Maillet S, Bouyge-Moreau I, Donnadieu E, Bonneville M, Scotet E.

J Immunol. 2006 Feb 1;176(3):1386-93.

40.

V gamma 9V delta 2 T cell response to colon carcinoma cells.

Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, Bonneville M, Jotereau F.

J Immunol. 2005 Oct 15;175(8):5481-8.

41.

Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I.

Scotet E, Martinez LO, Grant E, Barbaras R, Jenö P, Guiraud M, Monsarrat B, Saulquin X, Maillet S, Estève JP, Lopez F, Perret B, Collet X, Bonneville M, Champagne E.

Immunity. 2005 Jan;22(1):71-80.

42.
43.

Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells.

Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, Maillet S, Hurwitz R, Kursar M, Bonneville M, Kaufmann SH, Schaible UE.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10685-90. Epub 2004 Jul 8.

44.

Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1.

Landais E, Saulquin X, Scotet E, Trautmann L, Peyrat MA, Yates JL, Kwok WW, Bonneville M, Houssaint E.

Blood. 2004 Feb 15;103(4):1408-16. Epub 2003 Oct 16.

45.

Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.

Bortoletto N, Scotet E, Myamoto Y, D'Oro U, Lanzavecchia A.

Eur J Immunol. 2002 Nov;32(11):3102-7.

46.

+1 Frameshifting as a novel mechanism to generate a cryptic cytotoxic T lymphocyte epitope derived from human interleukin 10.

Saulquin X, Scotet E, Trautmann L, Peyrat MA, Halary F, Bonneville M, Houssaint E.

J Exp Med. 2002 Feb 4;195(3):353-8.

47.

Immunodominant CD8 T cell response to Epstein-Barr virus.

Houssaint E, Saulquin X, Scotet E, Bonneville M.

Biomed Pharmacother. 2001 Sep;55(7):373-80. Review.

PMID:
11669500
48.

Molecular regulation of CC-chemokine receptor 3 expression in human T helper 2 cells.

Scotet E, Schroeder S, Lanzavecchia A.

Blood. 2001 Oct 15;98(8):2568-70.

49.

Frequent recognition of BCRF1, a late lytic cycle protein of Epstein-Barr virus, in the HLA-B*2705 context: evidence for a TAP-independent processing.

Saulquin X, Bodinier M, Peyrat MA, Hislop A, Scotet E, Lang F, Bonneville M, Houssaint E.

Eur J Immunol. 2001 Mar;31(3):708-15.

50.

Regulation of inhibitory and activating killer-cell Ig-like receptor expression occurs in T cells after termination of TCR rearrangements.

Vely F, Peyrat M, Couedel C, Morcet J, Halary F, Davodeau F, Romagne F, Scotet E, Saulquin X, Houssaint E, Schleinitz N, Moretta A, Vivier E, Bonneville M.

J Immunol. 2001 Feb 15;166(4):2487-94.

Supplemental Content

Loading ...
Support Center